Life Sciences Executive Search For European Boards

Life sciences executive search is not healthcare recruiting with a different label. It is the discipline of placing leaders who can hold three contradictory pressures at once: a regulator who wants more data, an investor who wants faster milestones, and a commercial market that wants both speed and certainty. Most search engagements that fail in this sector fail because they treat one of those pressures as the main brief and the other two as background noise. If you're the TA leader running those searches, you're the one who has to defend the brief in front of all three stakeholder groups at the same time.

That balancing act rarely sits on one sub-vertical either. Most life sciences TA leaders cover several. The same person ends up running a CMO search inside a clinical-stage biotech in the morning, a head of regulatory for a device subsidiary in the afternoon, and a commercial lead for a diagnostic spin-out the next week. This article covers what changes when a candidate has to read regulators, capital markets, and commercial buyers in the same week, where standard retained search breaks down on your watch, and how to think about leadership hiring as a portfolio discipline rather than a string of single-vacancy events.

The overview of how executive search functions explains the standard process; this article focuses on what changes when the company runs on regulatory clocks and capital runways at the same time.

Key Takeaways

• Life sciences leadership is a three-axis problem. The right executive must read regulators, capital markets, and commercial buyers in the same week, often in the same meeting. The TA leader running the search has to defend all three axes against stakeholder groups that each want their own to dominate the brief.
• Generalist search slates underperform here. Sector-naive recruiters optimize for resume keywords, not for the cross-functional judgment the role actually demands.
• The talent pool is narrow by design. Specialization by therapeutic area, modality, and development stage limits interchangeability at the top, especially in Europe where the senior pool sits inside a handful of established hubs.
• Speed is structural, not cosmetic. Capital cycles and regulatory windows mean a slow search is not just inefficient, it is value-destroying. Every additional month of executive vacancy compresses optionality.
• Single-search thinking is the bottleneck. Life sciences TA leaders rarely face one mandate at a time. The companies that get hiring right treat the executive bench as a portfolio across pharma, biotech, devices, and diagnostics, not as a string of isolated searches.

Why Life Sciences Executive Search Differs from Standard Recruiting

Most C-suite searches reward general management ability. Life sciences searches reward something narrower: the ability to operate inside heavily regulated, capital-intensive, scientifically complex businesses without losing speed.

The European context makes this sharper. In 2025, the European Medicines Agency recommended 104 medicines for marketing authorisation, including 38 with new active substances never previously authorised in the EU. Each of those approvals sits inside a multi-stage process that runs in parallel with HTA review, country-by-country reimbursement negotiation, and (for advanced therapies) a separate set of post-authorisation obligations. A leader who has only run U.S.-pathway programs will misjudge how those layers interact in practice.

The talent pool is also narrower than it looks on a job board. Life sciences executive talent is segmented by therapeutic area, modality, regulatory pathway, development stage, and function, which means an immuno-oncology biologics leader cannot simply move into a rare-disease small-molecule program. The same logic applies to medical-device regulatory leaders versus pharma regulatory leaders. This is why generalist C-suite recruiting approaches often miss in this sector: they evaluate seniority and brand, not the cross-axis pattern recognition the role demands.

Generalist search firms evaluate seniority and brand. Life sciences search has to evaluate cross-axis pattern recognition, which is a different muscle entirely.

The Three Disciplines a Modern Life Sciences Leader Must Span

The reader test is simple. If a candidate cannot hold a credible thirty-minute conversation in any one of the three areas below, they are not a life sciences executive. They are a specialist who happens to work in healthcare.

Regulatory fluency

Regulatory leadership is no longer a back-office function. It is a strategic discipline that shapes valuation, deal structure, and launch sequencing. EMA pathways, FDA submission strategy, MDR and IVDR realities for device companies, and the new EU HTA Regulation each carry implementation risk that a non-specialist CEO will not see until the timeline slips.

A 2025 peer-reviewed analysis published in Frontiers in Medicine found that the median time from the start of the marketing authorisation procedure to final approval by the European Commission was 441 days for advanced therapy medicinal products approved between 2008 and 2024, with PRIME-designated products moving meaningfully faster. Translating that data into a coherent filing strategy across markets is leadership work, not staff work.

Commercialization across fragmented markets

European commercialization is structurally harder than U.S. commercialization because there is no single payer or single launch. A new medicine has to navigate German AMNOG, French HAS, NICE in the UK, and the patchwork of southern European reimbursement bodies, each with its own evidence requirements and timelines.

A commercial leader who cannot read those systems will leak value at every market entry. This judgment does not show up on a CV. It shows up in the questions a candidate asks during the second interview, and in the speed at which they identify which national reimbursement body will be the binding constraint for the launch.

Capital fluency

Life sciences is a capital-intensive sport, and the European capital base is structurally thin. According to the European Commission, European venture-capital investment in health biotech accounts for just 7% of the global market, compared with 63% in the United States and 14% in China, and 66 out of 67 EU biotechnology firms chose to list on non-EU stock exchanges from 2019 to 2025.

A CEO or CFO who cannot run a credible Series B narrative for a U.S.-led syndicate, or who has never bridged a European pre-IPO company onto Nasdaq, is a real liability for a board that needs to extend runway in a tight window.

When the Standard Search Model Breaks (and What to Look For Instead)

This is where many life sciences searches quietly come apart on the TA leader's watch. The signals are recognizable, and the TA leader running the vendor relationship usually sees them first.

You are likely past the breaking point of the standard model if three or more of the following apply:

• The search has been open for more than five months and the shortlist has not changed in the last six weeks.
• Your search firm is presenting candidates from outside life sciences and framing it as "fresh thinking."
• The strongest candidates on your slate have never operated in a European regulatory context, but the role is European-headquartered.
• Your runway has shortened by a quarter since the search opened and the role is still vacant.
• The board is starting to suggest "interim coverage" without a clear conversion plan.

If that pattern is forming, the question is not whether to push the current process harder. It is whether the operating model behind the search is fit for purpose, and whether you have the credibility with the board to propose a different one.

Doing nothing here is a decision. Every additional month of executive vacancy in a clinical-stage company compresses optionality on a financing round, pushes a regulatory milestone into the next budget cycle, or hands a competitor an open lane. The TA leader absorbs both the vacancy cost and the conversation with the board about why the search hasn't closed.

The pipeline pressure is visible in the data. Russell Reynolds Associates' Global CFO Turnover Index, which tracks the world's twelve largest stock indices, found that 60% of healthcare-sector CFOs retired or moved to a board role in 2024, above the global average of 54%. The same pattern shows up in CMO, CSO, and head-of-regulatory roles. The pool of available, sector-fluent executive talent is tighter than the headline numbers suggest, which makes vendor selection more consequential, not less.

The standard checklist (industry experience, references, retainer structure) is necessary but no longer sufficient. The broader guidance on how to evaluate executive search firms covers the structural questions in detail. For life sciences specifically, three additional probes are worth running before signing a retainer:

• Ask the firm to walk you through a placement that failed within eighteen months. The answer reveals whether they understand the difference between assessing capability and assessing fit at the regulatory-commercial-capital intersection.
• Ask how they validate scientific credibility beyond resume credentials. Strong firms can point to peer references, publication track record, regulatory outcomes, and program leadership.
• Ask how they think about therapeutic-area adjacencies. A firm that cannot articulate when an oncology leader can credibly cross into immunology, or when a small-molecule executive can cross into biologics, will produce slates that look diverse but read as random.

The choice in front of you is not subtle. Continue with a firm that can't answer those three probes and accept the consequences: a search that runs past the runway, surfaces candidates the board could have found through its own network, and lands a hire whose fit on the binding axis is unknown. Or change the vendor relationship before the next mandate opens, and give the board a defensible reason why this search will look different from the last.

Where Pharma and Biotech Diverge

Life sciences as a category is the right unit of analysis for portfolio thinking. It is the wrong unit of analysis for an actual search brief.

Pharmaceutical leadership hiring sits inside organizations with established commercial infrastructure, regulatory affairs functions that already operate at scale, and brand-defense responsibilities that shape every executive decision. The compliance environment is dense, the stakeholder map is long, and the cost of an executive misfire compounds across years of pipeline planning. The deeper treatment of pharmaceutical executive recruiters and how they work covers where compliance and large-org dynamics reshape the search brief in pharma specifically.

Biotech leadership hiring, especially in VC-backed companies, is a fundamentally different problem. The clock is set by capital, the team is small enough that a single bad hire is structural, and scientific founders often need a partner who can translate science into a fundable narrative. The companion piece on biotech executive search for VC-backed companies covers founder-CEO transitions, scaling pre-revenue leadership teams, and the specific challenges of building without commercial revenue to absorb errors.

Pharma rewards leaders who can run a regulated machine. Biotech rewards leaders who can build one.

Treating these as the same brief produces shortlists that fit neither, and a TA leader who tries to use the same vendor for both will absorb the brief mismatch first.

Building Leadership Pipelines Beyond a Single Search

The single-search mindset is part of why life sciences leadership hiring stays expensive and slow. TA leaders that treat each vacancy as an isolated event end up paying for the search infrastructure twice: once for the named placement, once for the institutional knowledge that walks out the door with each engagement. The companies that get this right treat senior hiring as a portfolio across the executive bench and the senior-VP layer underneath it, not as a sequence of one-off retainers.

Three operational shifts help here.

The first is treating interim or fractional leadership as a deliberate bridge rather than an emergency measure. Interim and fractional executive hiring covers when this fits, how it differs from staffing, and what to expect on cost and risk. For life sciences specifically, an interim chief medical officer or interim head of regulatory can hold a regulatory window open while a permanent search runs at the proper depth. The interim is not a placeholder; it is a strategic bridge that prevents the permanent search from being rushed against a milestone the company can't postpone.

The second is rethinking how recruiting capacity is accessed at the operational layer below the C-suite. Life sciences companies preparing for a major launch, a clinical readout, or a Series B often need specialist regulatory affairs directors, clinical operations leaders, and commercial heads in parallel with their executive searches. Three sequential retained searches at one-third of first-year cash compensation each compounds into a fee envelope most clinical-stage companies cannot justify.

This is where recruiter marketplaces and on-demand recruiting provide a different shape of capacity: access to specialist recruiters with deep sector experience, on a per-role basis, without the multi-year retainer structure of a traditional firm. The TA leader keeps a single relationship instead of managing three vendors with conflicting timelines.

The third is portfolio thinking across sub-verticals. A life sciences TA leader whose remit spans pharma, biotech, devices, or diagnostics rarely needs the same firm for all four. A marketplace model gives parallel access to country-specialist and sub-vertical specialist recruiters under one coordination layer, which scales up and down with the financing and pipeline cycle without rebuilding the vendor relationship each time.

For European companies hiring across DACH, Benelux, and the Nordics, country-level recruiter expertise is often more important than the brand on the executive search retainer. The senior reimbursement leader who knows how G-BA actually decides a benefit assessment is not interchangeable with a leader who has run the equivalent submission in France or the Netherlands.

What You're Really Buying

Life sciences leadership hiring is not a sourcing problem. It is a portfolio-judgment problem, and the TA leader running the searches is the one paying the gap between what was hired and what the company actually needed.

Life sciences leadership hiring is not getting easier, and it is not going to. The pharmaceutical industry invests €55 billion in European research and development each year and supports 2.6 million jobs across the region, but the capital base, the regulatory environment, and the talent pool are all under structural pressure at the same time. Companies that keep running searches as if they are filling a single role with a single search firm will keep paying for the gap between what they hired and what the company actually needed.

In life sciences, you are not hiring an executive. You are buying a portfolio of judgment across regulation, commercialization, and capital. If your search process cannot tell you which of those three the candidate is strongest in, and which they have never actually carried alone, the search has not happened yet.

The TA leaders who get this right do not run more searches. They run the same number, with sharper briefs, vendor relationships that scale across mandates instead of restarting each time, and an interim or marketplace layer that takes the pressure off the permanent search. The question is not whether your next mandate will close. It is whether the model behind it can survive the next three.

Frequently Asked Questions

What is life sciences executive search?

Life sciences executive search is the practice of recruiting senior leaders (C-suite, VP, and equivalent) for companies operating in pharma, biotech, medical devices, diagnostics, and related categories. It is distinct from healthcare executive search, which typically focuses on hospitals, payers, and providers. The defining feature is the requirement to assess candidates across regulatory, commercial, and capital fluency rather than any one of those in isolation.

How long does a life sciences executive search take?

A well-run retained search for a sector-specialized C-suite role typically takes between fourteen and twenty-four weeks from kickoff to signed offer in the European market. Searches that run longer usually signal a brief that is too narrow, a compensation package that is below market, or a search firm without genuine therapeutic-area depth. The TA leader running the vendor relationship should set a clear review point at the twelve-week mark, with explicit criteria for what would trigger a change in approach.

How does life sciences executive search compare to using a recruiter marketplace?

A retained search firm runs a single, deeply researched search for a named senior role, usually with a retainer split across milestones. A recruiter marketplace gives a company on-demand access to a curated pool of specialized recruiters who can run multiple parallel searches across functions and geographies, without long-term contracts. For most life sciences companies, the two are complementary: retained search for the named C-suite role, marketplace access for the specialist VP and director layer that has to be hired alongside.

When is interim leadership the right answer in life sciences?

Interim leadership fits when there is a regulatory milestone, fundraising round, or commercial launch within the next two quarters and the permanent search will not close in time. It is also appropriate for companies in transition (post-acquisition, pre-IPO, leadership turnover) where a fully tenured search would distract from operational priorities. It is not a substitute for a permanent hire when the role is structurally permanent.

What does a life sciences executive search firm typically cost in Europe?

Retained executive search fees in Europe usually fall between 28% and 33% of first-year cash compensation, with a portion paid as a retainer at engagement, against milestones, and on placement. For senior C-suite roles, total fees commonly land between €100,000 and €250,000 depending on seniority, geography, and complexity. Specialist life sciences firms typically sit at the upper end of that range because of the narrowness of the talent pool.

How do I run leadership searches across multiple life sciences sub-verticals without managing three vendor relationships?

A TA leader whose remit spans pharma, biotech, devices, or diagnostics rarely needs the same firm for all four. Pharma searches reward firms with deep large-org compliance experience; biotech rewards firms that understand investor-syndicate dynamics; device companies need firms that read MDR and IVDR fluently. Three sequential retained relationships across sub-verticals compound into a fee envelope and a coordination cost most life sciences companies cannot justify. A recruiter marketplace gives parallel access to sub-vertical and country specialists under one coordination layer, with the relationship scaling up or down with the financing and pipeline cycle. The TA leader keeps a single point of contact instead of managing three vendors with conflicting timelines and incentive structures.